Jasper Therapeutics, Inc. 8K

Jasper Therapeutics completed an all‑stock acquisition of Kira Pharmaceuticals, arranged a $132 million private placement and a $12 million out‑licensing deal with Mirador Therapeutics, and restructured its ownership and pipeline to fund operations and key clinical milestones through the second half of 2028.

On July 16, 2026, Jasper Therapeutics, Inc. announced that it has completed an all‑stock acquisition of Kira Pharmaceuticals, forming a combined company focused on biologic therapies for immunologically driven disorders, alongside entering into a concurrent private placement of non‑voting convertible preferred stock expected to raise approximately $132 million and an out‑licensing agreement under which Kira has granted Mirador Therapeutics rights to KP‑301 and KP‑402 in exchange for a $12 million upfront payment and potential milestones. The merger and financing are expected to fund the combined company’s operations through the second half of 2028 and support advancement of a consolidated pipeline including KP‑104, briquilimab, and KP‑701 through multiple key clinical milestones, while the company’s capital structure will shift so that pre‑transaction Jasper equityholders own about 6.68%, former Kira equityholders own about 49.86%, and private placement investors own about 43.46% of Jasper’s common stock on an as‑converted, fully diluted basis. The preferred stock will automatically convert into Jasper common stock (61 shares per preferred share) upon Jasper stockholder approval in accordance with Nasdaq rules, and existing Jasper stockholders as of immediately before closing will receive non‑transferable contingent value rights entitling them to up to $30 million in aggregate payments upon monetization of a priority review voucher for briquilimab by December 31, 2028 or an acquisition of the combined company after receipt of such voucher.

Filing Facts

CIK

1788028

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-078781

Alert Tier

8